Posted by Michael Wonder on 26 Feb 2022
FDA accepts for review Pfizer’s supplemental application for Abrilada (adalimumab-afzb) interchangeability
25 February 2022 - Pfizer today announced that the U.S. FDA has accepted for review the prior approval supplement to the Biologics License Application for Abrilada (adalimumab-afzb) as an interchangeable biosimilar to Humira (adalimumab).
The Biosimilar User Fee Act goal date for an FDA decision is in Q4, 2022.
